Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

Google and Perceptra, a Google technology licensing partner, are joining forces to provide AI-powered diabetic-retinopathy (DR) screening to around 1 million people in underserved communities across ...

A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...